In March, the Food and Drug Administration (FDA) approved semaglutide (brand name: Wegovy) for just that purpose after a study published last November showed that the medication lowers certain peoples risk for those events by as much as 20%
S2CID 24097516
At lower doses, patients also lost weight: At a 10 mg dosage, the average weight loss was about 21.4%, or about 48 pounds
Byrne said GLP-1 patients often walk into his office claiming they look "hollowed out." Think sunken cheeks, gaunt eyes, sagging neck skin, surprise jowls and temples that seem to have caved in overnight
Inhibition of p38 mitogen-activated protein kinase interferes with cell shape changes and gene expression associated with Schwann cell myelination
Common side effects may include temporary skin irritation, mild redness, or sensitivity at application sites, particularly during initial treatment phases